

WEBINAR INVITATION

A Swedish-American Journey of Innovation in Cancer Research

February 2, 2021 between 10:00 AM – 12:00 PM (EST)

Welcome to a seminar focusing on the triple helix model, the Swedish teachers' exemption, and how these frameworks spur academic innovation from the lab to bedside care.


The seminar is co-hosted by the Embassy of Sweden in Washington, DC, Dana-Farber Institute of Cancer, Harvard Medical School, Uppsala University, and Oncopeptides AB.

CLICK HERE TO REGISTER

After registering, you will receive a confirmation email containing information on how to join the webinar.

@SwedeninUSA @DanaFarber @uppsalauni @OncopeptidesUS
#myeloma #hematology #lifescience

- 10:00 AM **Welcome and Introduction**
H.E. Karin Olofsdotter, Ambassador of Sweden to the United States, and Professor Ola Landgren, MD PhD, University of Miami
- 10:10 AM **Keynote: “Multiple Myeloma – 20 Years of Research is Transforming Patients’ Lives”**
Dr. Paul Richardson, RJ Corman Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, and Patient
- 10:25 AM Short Film
- 10:30 AM **Panel Discussion: “The Swedish Innovation Model”**
Moderator: Ola Landgren, MD PhD, University of Miami
Panelists:
Dr. Joachim Gullbo, Associate Professor in Experimental Clinical Pharmacology, Theradex Oncology, Uppsala University, and Co-Founder and Senior R&D Strategist, Oncopeptides; Professor Mats Larhed, Vice-Rector of Disciplinary Domain of Medicine and Pharmacy, Uppsala University; and Professor Henric Johnson, Counselor, Science and Innovation, Embassy of Sweden in Washington, DC
- 11:00 AM Short Film



- 11:05 AM **Panel Discussion: “Swedish-US Research Collaboration – Driving Innovation in Cancer”**
Moderator: Ola Landgren, MD PhD, University of Miami
Panelists:
Mr. Marty J Duvall, CEO, Oncopeptides;
Professor Kenneth Anderson, Kraft Family Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute;
Dr. Jenni Nordborg, Head of the Office for Life Sciences, Government Offices of Sweden;
Ms. Suzanne Håkansson, Senior Director, Governmental Affairs Europe and Nordic, AstraZeneca; and
Professor Tobias Sjöblom, Department of Immunology, Genetics, and Pathology, Uppsala University
- 11:45 AM **Concluding Remarks**
- 12:00 PM **End of Seminar**



UPPSALA
UNIVERSITET



Dana-Farber
Cancer Institute



oncopeptides



Embassy of Sweden
Washington